Eli Lilly and Company (LLY) on Monday announced that it would acquire a small biopharmaceutical startup that develops cancer treatment, Loxo Oncology (LOXO), for $8 billion, in its largest and latest in a series of transactions to broaden its own portfolio of oncology drugs. The deal, valued at $235 per share comes at a hefty … Continue reading In a massive deal, Eli Lilly acquires Loxo Oncology